Practices evaluating a regenerative service line almost always ask the cost question first and the return question second. That order is backwards, and it is why so many of the estimates floating around are useless. The startup number is comparatively knowable. What determines whether the line works is the cost of acquiring and converting a patient, which most projections leave out entirely.
Standing up a regenerative medicine service line typically requires investment across five areas: clinical capability, biologics sourcing, facility and compliance, staffing, and the commercial build. The first four are one-time and predictable. The fifth is ongoing, is the largest determinant of profitability, and is the one most practices fail to budget.
The Five Cost Areas
Clinical capability. Image guidance if you do not already have it, procedural supplies, and training time for whoever performs the procedures. Practices already doing guided injections carry very little cost here; practices starting from nothing carry the most.
Biologics sourcing. This is the recurring cost of goods, and it varies more between suppliers than most practices expect. It is also where verification matters: lab-confirmed cell counts cost more and are worth it, because your marketing credibility eventually depends on being able to substantiate what you deliver.
Facility and compliance. Appropriate procedure space, storage and handling requirements, insurance coverage changes, and legal review of your structure. This line is small in dollars relative to the others and disproportionately expensive to get wrong.
Staffing. If you need a medical provider you did not previously employ, this is usually your largest single line. If you already have one, the staffing cost shifts to the commercial side.
The commercial build. Someone to run consultations and follow-up, a CRM, a proposal mechanism, and eventually advertising. This is the line practices omit, and it is the one that decides the outcome.
Why the Commercial Line Dominates
Here is the arithmetic that matters. Clinical setup is largely a one-time cost you amortize across every case you ever perform. Patient acquisition is a per-case cost you pay forever.
A practice that spends heavily on setup but acquires patients efficiently reaches profitability quickly. A practice that spends nothing on setup but pays too much per acquired patient never does, regardless of how lean the launch was. Over any reasonable horizon, acquisition cost swamps startup cost.
This is why the honest version of the cost question is not "what does it cost to start" but "what will it cost me to produce one paying patient, repeatedly." The method for calculating that is in patient acquisition cost for stem cell clinics.
The Return Side: Work Backward From Case Value
Regenerative cases typically land somewhere between $10,000 and $30,000 depending on protocol complexity, number of sites, and market. Your actual average will be lower than your list price once discounts, financing fees, and protocol mix are accounted for, and the real figure is the one to model with.
From that, three numbers determine everything: cost to deliver the case, cost to acquire the patient, and your close rate on consultations.
Close rate is the lever practices consistently underweight. A practice converting twenty-five percent of consults and one converting forty-five percent have completely different businesses on identical lead flow and identical spend. The second one can afford acquisition costs that would bankrupt the first. That is why the commercial build is not overhead — it is the highest-return investment in the entire project.
Modeling Breakeven Honestly
Do this before committing, on your own numbers rather than someone's benchmark.
Take your realistic average case value. Subtract cost to deliver. Subtract your expected acquisition cost per closed patient. What remains is contribution per case. Divide your monthly fixed costs for the service line — provider time, coordinator salary, software, facility allocation — by that contribution figure, and you have the number of cases per month required to break even.
Then apply the honesty test: is that number realistic given your patient base and market? If the model says you need fourteen cases a month and your existing chart base plausibly supports five, you have learned something important for the price of an afternoon rather than the price of a launch.
Model a slow ramp as well. Most practices do not hit steady-state volume for six to twelve months, and the cash requirement during that ramp is what actually strains a practice — not the initial purchase.
Where the Money Quietly Leaks
Discounting. A ten percent discount on a $22,000 case comes almost entirely out of contribution, not out of revenue in any meaningful sense. Two or three casual discounts a month can erase the profit on a fourth case. Our pricing strategy guide covers holding price without losing the patient.
Unworked leads. Every inquiry you paid for and did not follow up is pure loss, and it is the most common leak. Most practices have more revenue sitting in their existing lead list than in next month's ad budget — see follow-up sequences that revive dead leads.
No-shows. A consultation that does not happen consumed acquisition cost and returned nothing. Confirmation sequences are nearly free and move this measurably, as covered in how to reduce no-show consultations.
Untrained consultations. The largest leak of all, and invisible on any spreadsheet. Patients who would have proceeded, lost in a conversation nobody was trained to run.
A Staged Approach That Limits Downside
You do not have to commit to the full build to find out whether the line works.
Stage one is validation using your existing patient base and minimal outside spend. Establish sourcing, price the offering, train whoever will run consultations, and work your own charts. This costs relatively little and answers the only question that matters: will patients who already trust you pay for this?
Stage two, once you are converting reliably, adds acquisition spend. You now have a measured close rate, which means you can calculate what you can afford to pay for a lead instead of guessing.
Stage three is scale — additional provider hours, expanded indications, more spend behind whatever cleared your threshold.
Practices that run these stages in order rarely lose badly, because each stage is funded by evidence from the one before. Practices that jump to stage three carry the full cost structure while still learning whether they can convert.
Frequently Asked Questions
What is the single largest cost?
Over any meaningful period, patient acquisition. Startup costs are one-time and amortize across every case; acquisition is paid on every patient forever. Practices that optimize only the launch budget usually mis-plan the business.
Can we start without hiring anyone new?
Sometimes clinically, rarely commercially. If an existing team member can be trained to own consultations and follow-up, you can begin without a new hire — but somebody has to own it as a real responsibility, not as an addition to a full role.
How long until the service line is profitable?
Commonly six to twelve months, driven mostly by how fast you build a working consultation process rather than by clinical readiness. Practices that validate on their existing patient base first tend to reach it sooner.
Is it cheaper to add this to an existing practice than to open a clinic?
Substantially, yes. You already carry the facility, the staff, and most importantly the patient relationships. The patient base is the expensive asset in this business, and an established practice already owns it.
What return should we expect?
Calculate it from your own numbers rather than an industry figure. Contribution per case minus acquisition cost, multiplied by realistic volume, against your fixed costs. Any projection that skips acquisition cost is not a projection.
Want the model run on your numbers? Book a free strategy call.